ResultsIQ

ResultsIQ › Latest results › Poly Medicure Limited

Poly Medicure Limited Q4 FY25 results deck summary

NSE: POLYMED · BSE: 531768

Results deck of 6 May 2025, summarised by AI from the filing.

Launched over 30 new products in FY25 vs 19 in FY24; R&D team strength of over 60

Key takeaways

  1. R&D Launched over 30 new products in FY25 vs 19 in FY24; R&D team strength of over 60

Original filing on BSE

Poly Medicure Limited Q1 FY27 results

As filed: Revenue ₹525 cr (+30% year on year), EBITDA ₹125 cr (+18% year on year), PAT ₹85.3 cr (−8% year on year), EBITDA margin 23.8% (−249 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹535 cr (+21% year on year), EBITDA ₹110 cr (−8% year on year), PAT ₹65.0 cr (−29% year on year), EBITDA margin 20.7% (−656 bps). Score 32 of 100, Below trend. Revenue growth was above the company's own trend; EBITDA and profit growth were well below it. EBITDA margin fell 656 bps year on year. Profit fell 8% from last quarter. Revenue rose ₹93.5 cr on a year ago, more than the ₹63.0 cr it added the year before. Share price after the results: +6.7% in 30 days (Nifty 500: +0.9%).
  • Q3 FY26: Revenue ₹494 cr (+16% year on year), EBITDA ₹111 cr (−3% year on year), PAT ₹70.8 cr (−17% year on year), EBITDA margin 22.5% (−460 bps). Score 14 of 100, Below trend. Revenue growth was in line with the company's own trend; EBITDA and profit growth were well below it. EBITDA margin fell 460 bps year on year. Other income 27% of PBT. Profit fell 23% from last quarter. Profit rose ₹-14.2 cr on a year ago, against ₹20.0 cr the year before. Share price after the results: −10.6% in 29 days (Nifty 500: −4.5%).
  • Q2 FY26: Revenue ₹444 cr (+6% year on year), EBITDA ₹115 cr (0% year on year), PAT ₹92.0 cr (+6% year on year), EBITDA margin 25.9% (−148 bps). Score 9 of 100, Below trend. Revenue, EBITDA and profit growth were well below the company's own trend. EBITDA margin fell 148 bps year on year. Other income 28% of PBT. Revenue rose ₹24.0 cr on a year ago, against ₹83.0 cr the year before. Share price after the results: −1.9% in 30 days (Nifty 500: 0.0%).
  • Q1 FY26: Revenue ₹403 cr (+5% year on year), EBITDA ₹106 cr (+2% year on year), PAT ₹93.0 cr (+26% year on year), EBITDA margin 26.3% (−71 bps). Score 27 of 100, Below trend. Revenue and EBITDA growth were well below the company's own trend; profit growth was in line with it. EBITDA margin fell 71 bps year on year. Other income 34% of PBT. Revenue fell 9% from last quarter. Revenue rose ₹18.0 cr on a year ago, against ₹64.0 cr the year before. Share price after the results: +5.5% in 28 days (Nifty 500: +0.6%).
  • Q4 FY25: Revenue ₹441 cr (+17% year on year), EBITDA ₹120 cr (+25% year on year), PAT ₹92.0 cr (+35% year on year), EBITDA margin 27.2% (+181 bps). Score 70 of 100, Above trend. Revenue growth was well below the company's own trend; EBITDA growth was in line with it; profit growth was above it. EBITDA margin rose 181 bps year on year. Revenue rose ₹63.0 cr on a year ago, against ₹71.0 cr the year before. Share price after the results: −19.6% in 30 days (Nifty 500: +4.5%).
  • Q3 FY25: Revenue ₹424 cr (+25% year on year), EBITDA ₹115 cr (+29% year on year), PAT ₹85.0 cr (+31% year on year), EBITDA margin 27.1% (+95 bps). Score 69 of 100, Above trend. Revenue, EBITDA and profit growth were above the company's own trend. EBITDA margin rose 95 bps year on year. Revenue rose ₹84.0 cr on a year ago, more than the ₹55.0 cr it added the year before.
  • Q2 FY25: Revenue ₹420 cr (+25% year on year), EBITDA ₹115 cr (+37% year on year), PAT ₹87.0 cr (+40% year on year), EBITDA margin 27.4% (+246 bps). Score 81 of 100, Above trend. EBITDA margin rose 246 bps year on year. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Poly Medicure Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.